Influence of Transfusion to the Growth of Cancer-Soluble MHC Class I

异体输血似乎会诱导受者的免疫调节，这可能会增加癌症复发的可能性。在这项研究中，我们回顾分析了接受胸段食道癌切除手术的患者，并比较了接受异体输血和自体输血的患者的结果。比较影响预后的临床病理因素、生存率和无病生存率。我们发现影响预后的临床病理因素在两组中相似，但在接受自体输血的患者中有明显的生存优势。食道癌的复发率和复发后的生存时间没有显著差异。另一方面，输自体血的患者在复发前的无病生存期显著延长，多因素分析…更多的研究表明，自体输血是影响食道癌患者生存的独立预后因素。我们的临床研究结果表明，同种异体血液中存在的一种或多种未知介质可能抑制了对食道癌细胞的免疫反应。为了验证这一想法，我们使用了一个动物模型来确定输注新鲜或储存的血液中存在的可溶或不溶因子是否诱导免疫调节，从而促进体内实体瘤的生长。我们发现，输注所有同种异体血液产品会促进肿瘤生长，储存的同基因全血也是如此。新鲜的同基因血液和储存的同基因血液的上清液都没有促进肿瘤的生长。异体血和储存的同种异体血中明显存在的与S因子相关的免疫调节在输血后7天内开始促进肿瘤的生长。综上所述，这些研究结果强烈表明，如果可能，在癌症手术期间不应输入异体血液。较少

Allogeneic blood transfusion appears to induce immunomoduration in the recipient that may increase the likelihood of cancer recurrence. In the present study, we retrospectively analyzed patients who underwent esophagectomy for thoracic esophageal cancer and compared the outcomes of those who received allogeneic blood transfusions with those who received autologous ones. Compared were the clinicopathological factors influencing prognosis as well as the survival rates and disease-free survival. We found that theclinicopathological factors that infuluenced prognosis were similar in the two groups ; however, a definite survival advantage was evident among those who received the autologous blood transfusion. There was no significant difference in the rates at which esophageal cancer recurred or in survival time once it had recurred. On the other hand, disease-free survival prior to recurrence was significantly prolonged in patients transfused with autologous blood, and multivariate analysis … More showed autologous blood transfusion to be independent prognostic factor for the survival of patients with esophageal cancer. The results of our clinical study suggest the possibility that one or more as yet unknown mediators present in allogeneic blood suppresses immune responses to esophageal cancer cells. To test that idea, we employed an animal model to determine whether transfusion of a soluble or insoluble factors present in fresh or stored blood induces immunomoduration that promotes solid tumor growth in vivo. We found that transfusion of all allogeneic blood products enhanced tumor growth, as did stored syngeneic whole blood. Neither fresh syngeneic blood nor the supernatant from stored syngeneic blood promoted tumor growth. The immunomodulation associated with the factor(s) apparently present in allogeneic and stored syngeneic blood began to enhance tumor growthwithin 7 days after transfusion. Taken together, there findings strongly suggest that, if possible, allogeneic blood should not be transfused during cancer surgeries. Less